The drug was initially approved for treating adult patients with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy (10). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.